从临床前疗效到有希望的临床试验,延迟1型糖尿病
J Jason Collier1, Daniel S Hsia2, Susan J Burke1
1Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA.
Pharmacological research
|August 14, 2024
概括
新的免疫学和小岛生物学的研究表明,通过调节免疫系统,有可能延迟1型糖尿病 (T1D). 像巴里西提尼布和特普利祖马布这样的疗法为保护小岛β细胞功能提供了希望,并可能预防或逆转T1D.
科学领域:
- 免疫学 免疫学 免疫学
- 岛屿生物学 岛屿生物学
- 内分泌学 在内分泌学.
背景情况:
- 早期对动物模型的研究,如非肥胖糖尿病 (NOD) 鼠,为使用环素和葡萄糖皮质类药物治疗1型糖尿病 (T1D) 的初步临床试验提供了信息.
- 在相关小鼠模型中进行的临床前研究为当前专注于免疫细胞功能和细胞因子信号通路的临床试验铺平了道路.
研究的目的:
- 对推迟T1D免疫调节的药物发展进行审查.
- 讨论从临床前模型向临床试验的过渡.
- 突出针对免疫路径的新型治疗策略.
主要方法:
- 在动物模型 (例如,NOD小鼠) 中使用环素和葡萄糖皮质类药物进行的临床前研究的审查.
- 对针对免疫细胞功能和细胞因子信号的当代临床试验的分析.
- 检查特定的免疫调节剂,如巴里西替尼和特利祖马布.
主要成果:
- 临床前发现指导了早期临床试验,证明了免疫调节的潜力.
- 巴里西丁尼布 (JAK1/2抑制剂) 和特普利祖马布 (抗CD3抗体) 在维护β细胞功能方面表现有前途.
- 与较旧的治疗方法相比,治疗策略提供了更好的疗效,并减少了副作用.
结论:
- 免疫系统调节是缓解T1D自身免疫力的可行策略.
- 向治疗和风险分层临床试验正在推动T1D预防.
- 这些进展促进了对T1D的潜在预防和逆转的乐观态度.
相关概念视频
01:22Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
01:22Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
01:15Diabetes: Management and Pharmacotherapy
246
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
246
01:24Glucagon-like Receptor Agonists
308
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
308
01:15Diabetes: Symptoms, Diagnosis, and Complications
520
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
520
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183